Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Medical oncology].

M S Aapro1

  • 1IMO, Clinique de Genolier, 1272 Genolier. maapro@genolier.net

Revue Medicale Suisse
|February 9, 2006
PubMed
Summary

This review examines randomized clinical trials for new anticancer drugs, highlighting challenges in assessing clinical significance and patient benefit for solid tumors. It clarifies which treatments offer marginal versus substantial improvements, aiding physician decision-making.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

[Society face to cancer: awareness and social actions].

Revue medicale suisse·2015
Same author

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Cancer treatment reviews·2012
Same author

What do prescribers think of biosimilars?

Targeted oncology·2012
Same author

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

European journal of cancer (Oxford, England : 1990)·2010

Area of Science:

  • Oncology
  • Clinical Pharmacology

Context:

  • Increasing patient access to online medical information necessitates clear interpretation of new anticancer drug trial data.
  • Experts face challenges in differentiating clinically significant advancements from marginal improvements in cancer therapeutics.
  • The high cost of novel cancer drugs complicates treatment decisions, especially when survival benefits are not definitively established.

Purpose:

  • To review key randomized clinical trials for novel anticancer agents targeting solid tumors.
  • To assess the clinical significance and patient impact of recent advancements in cancer drug development.
  • To provide physicians with a clearer understanding of evidence-based treatment options.

Summary:

  • Summarizes results from major randomized clinical trials of new anticancer drugs for solid tumors.
  • Evaluates the real-world clinical significance and patient survival benefits derived from these trials.
  • Highlights instances where treatment advancements offer only marginal improvements.

Impact:

  • Aids oncologists in navigating the complex landscape of new cancer drug approvals and trial data.
  • Supports evidence-based clinical decision-making for solid tumor treatment.
  • Provides a foundation for understanding the value of novel cancer therapies beyond initial trial results.

Related Experiment Videos